Berapa harga Impact Therap-b (7630)

Harga Impact Therap-b (7630) adalah $1.85

Apa kapitalisasi pasar Impact Therap-b (7630)

Kapitalisasi pasar Impact Therap-b (7630) adalah $510.85M

Impact Therap-b (7630) Pemecahan Saham

IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.

Tahun	Pemecahan	Kelipatan	Kelipatan Kumulatif
Tidak cukup data untuk tanggal yang disediakan.

Tahun

Pemecahan

Kelipatan

Kelipatan Kumulatif

Tidak cukup data untuk tanggal yang disediakan.

Perusahaan	Jumlah pemecahan saham	Kelipatan Kumulatif	Negara
Eli Lilly and Company LLY.US	4	x15	US
Johnson & Johnson JNJ.US	7	x432	US
AbbVie Inc. ABBV.US	0	-	US
Roche Holding AG RO.SW	2	x10000	CH
Merck & Co., Inc. MRK.US	7	x226	US

Perusahaan

Jumlah pemecahan saham

Kelipatan Kumulatif

Negara